Acorda Therapeutics, Inc. (ACORQ) Financial Statements (2025 and earlier)

Company Profile

Business Address TWO BLUE HILL PLAZA
PEARL RIVER, NY 10965
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments29,97937,53645,63471,369125,839445,553
Cash and cash equivalents29,97937,53645,63471,36962,085293,564
Short-term investments     63,754151,989
Restricted cash and investments3816,88413,40012,91712,836532
Receivables17,29813,86617,00220,19322,08323,430
Inventory, net of allowances, customer advances and progress billings16,15512,75218,54828,67725,22129,014
Inventory16,15512,75218,54828,67725,22129,014
Prepaid expense5,2114,3126,57414,80711,57419,384
Asset, held-for-sale, not part of disposal group    71,795  
Other current assets5,7706,7659991,5773,56010,194
Total current assets:74,79482,115102,157221,335201,113528,107
Noncurrent Assets
Operating lease, right-of-use asset4,2215,2876,75118,48123,450
Property, plant and equipment2,0792,6034,3827,263142,52760,519
Intangible assets, net (including goodwill)22,987305,087335,980366,981402,329710,629
Goodwill      282,059
Intangible assets, net (excluding goodwill)22,987305,087335,980366,981402,329428,570
Restricted cash and investments2552556,18918,60930,270 
Other noncurrent assets4,189248111129411
Total noncurrent assets:33,731313,480353,313411,345598,605771,559
TOTAL ASSETS:108,525395,595455,470632,680799,7181,299,666
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities37,68333,48939,45050,32265,334125,741
Accounts payable13,3739,80910,84512,15526,25748,859
Accrued liabilities24,31023,68028,60538,16739,07776,882
Deferred revenue227384   
Debt186,143  68,6318,349616
Business combination, contingent consideration, liability2,1322,5321,9291,6241,8664,914
Other undisclosed current liabilities1,5881,54512,64616,67510,8368,985
Total current liabilities:227,77337,95054,025137,25286,385140,256
Noncurrent Liabilities
Long-term debt and lease obligation  167,031182,756183,374241,265343,140
Long-term debt, excluding current maturities  167,031178,670166,174218,269343,140
Liabilities, other than long-term debt38,70896,99267,55267,573154,783182,773
Deferred income tax liabilities  44,20213,93019,1169,581
Liability for uncertainty in income taxes     7,1007,700
Other liabilities8,1749,7815,91468825911,987
Operating lease, liability3,1664,3414,08617,20022,996
Business combination, contingent consideration, liability27,36838,66847,67146,57678,434163,086
Derivative instruments and hedges, liabilities   371,19359,409 
Other undisclosed noncurrent liabilities (315,912)  6,5266,46521,514
Total noncurrent liabilities:(277,204)264,023250,308257,473402,513547,427
Total liabilities:(49,431)301,973304,333394,725488,898687,683
Equity
Equity, attributable to parent(157,956)93,622151,137237,955310,820611,983
Common stock1241394848
Treasury stock, value(638)(638)(638)(638)(638)(2,133)
Additional paid in capital1,030,3831,029,8811,023,1361,007,790979,3881,005,105
Accumulated other comprehensive income (loss)1,425628(1,017)(2,803)(1,169)2,806
Accumulated deficit(1,189,127)(936,273)(870,357)(766,403)(666,809)(393,843)
Other undisclosed equity 315,912     
Total equity:157,95693,622151,137237,955310,820611,983
TOTAL LIABILITIES AND EQUITY:108,525395,595455,470632,680799,7181,299,666

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues117,633118,566129,071152,967192,408471,433
Cost of revenue(35,706)(39,695)(64,190)(40,981)(34,849)(143,994)
Cost of goods and services sold(15,283)(30,332)(40,787)(33,513)(34,849)(99,310)
Gross profit:81,92778,87164,881111,986157,559327,439
Operating expenses(346,879)(114,211)(143,919)(190,062)(530,490)(288,953)
Other undisclosed operating income (loss)    61,299 
Operating income (loss):(264,952)(35,340)(79,038)(78,076)(311,632)38,486
Nonoperating income (expense)(31,069)93(30,036)(29,591)37,384(18,063)
Investment income, nonoperating5301,90958164,1703,518
Other nonoperating income (expense)511,250(6)1671316
Interest and debt expense(31,533)27,14255,10055,10055,073(21,597)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes    (55,100)(55,073)21,596
Income (loss) from continuing operations before equity method investments, income taxes:(327,554)(8,105)(53,974)(107,667)(274,248)20,422
Other undisclosed income (loss) from continuing operations before income taxes31,533(27,142)(55,100)  1
Income (loss) from continuing operations before income taxes:(296,021)(35,247)(109,074)(107,667)(274,248)20,423
Income tax expense (benefit)43,167(30,669)5,1208,0731,28213,259
Income (loss) from continuing operations:(252,854)(65,916)(103,954)(99,594)(272,966)33,682
Income (loss) before gain (loss) on sale of properties:(103,954)(99,594)(272,966)33,682
Net income (loss) available to common stockholders, basic:(252,854)(65,916)(103,954)(99,594)(272,966)33,682
Interest on convertible debt  5,26312,4206,202  
Net income (loss) available to common stockholders, diluted:(252,854)(60,653)(91,534)(93,392)(272,966)33,682

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net income (loss):(252,854)(65,916)(103,954)(99,594)(272,966)33,682
Other comprehensive income (loss)7971,6451,786(1,634)(3,975)(4,052)
Other undisclosed comprehensive income      
Comprehensive income (loss):(252,057)(64,271)(102,168)(101,228)(276,941)29,630
Other undisclosed comprehensive loss, net of tax, attributable to parent      
Comprehensive income (loss), net of tax, attributable to parent:(252,057)(64,271)(102,168)(101,228)(276,941)29,630

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: